Biology Reference
In-Depth Information
[47] Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor
necrosis factor (TNF) and TNF receptor family members in the mouse and human. J
Biol Chem 2006;281(20):13964-71.
[48] Speiser DE, Bachmann MF, Frick TW, McKall-Faienza K, Griffiths E, Pfeffer K,
et al. TNF receptor p55 controls early acute graft-versus-host disease. J Immunol
1997;158(11):5185-90.
[49] Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, et al. Differential
effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute
graft-versus-host disease pathologies. Blood 1998;91(11):4051-5.
[50] Borsotti C, Franklin AR, Lu SX, Kim TD, Smith OM, Suh D, et al. Absence of donor
T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-
versus-tumor activity. Blood 2007;110(2):783-6.
[51] Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymor-
phism in the human tumor necrosis factor alpha promoter on transcriptional activa-
tion. Proc Natl Acad Sci U S A 1997;94(7):3195-9.
[52] Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, et al. Increased se-
rum levels of tumor necrosis factor alpha precede major complications of bone marrow
transplantation. Blood 1990;75(4):1011-6.
[53] Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, et al. Etanercept
plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood
2008;111(4):2470-5.
[54] Kennedy GA, Butler J, Western R, Morton J, Durrant S, Hill GR. Combination antithy-
mocyte globulin and soluble TNFalpha inhibitor (etanercept) +/− mycophenolate
mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow
Transplant 2006;37(12):1143-7.
[55] Herve P, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P, et al. Phase I-II
trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of
refractory severe acute graft-versus-host disease. Blood 1992;79(12):3362-8.
[56] Holler E, Kolb HJ, Wilmanns W. Treatment of GVHD—TNF-antibodies and related
antagonists. Bone Marrow Transplant 1993;12(Suppl. 3):S29-31.
[57] Noguchi M, Hiwatashi N, Liu Z, Toyota T. Secretion imbalance between tumour necro-
sis factor and its inhibitor in inflammatory bowel disease. Gut 1998;43(2):203-9.
[58] Sankary H, Chong A, Frye E, Scuderi P, Foster P, McChesney L, et al. Daily determina-
tion of serum lymphotoxin allows for accurate early diagnosis of hepatic allograft rejec-
tion. Transplant Proc 1993;25(1 Pt 2):928-30.
[59] Holzer G, Pfandlsteiner T, Blahovec H, Trieb K, Kotz R. Serum levels of TNF-beta and
sTNF-R in patients with malignant bone tumours. Anticancer Res 2003;23(3C):3057-9.
[60] Rocha V, Franco RF, Porcher R, Bittencourt H, Silva Jr WA, Latouche A, et al. Host
defense and inflammatory gene polymorphisms are associated with outcomes after
HLA-identical sibling bone marrow transplantation. Blood 2002;100(12):3908-18.
[61] Laas K, Peltomaa R, Kautiainen H, Leirisalo-Repo M. Clinical impact of switching
from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol
2008;27(7):927-32.
[62] Di Poi E, Perin A, Morassi MP, Del Frate M, Ferraccioli GF, De Vita S. Switching to etan-
ercept in patients with rheumatoid arthritis with no response to infliximab. Clin Exp
Rheumatol 2007;25(1):85-7.
[63] Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I,
et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes
from patients with Crohn's disease. Gastroenterology 2003;124(7):1774-85.
[64] Chiang EY, Kolumam GA, Yu X, Francesco M, Ivelja S, Peng I, et al. Targeted depletion of
lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat
Med 2009;15(7):766-73.
[65] Hsieh MH, Korngold R. Differential use of FasL- and perforin-mediated cytolytic
mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses.
Blood 2000;96(3):1047-55.
[66] Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, et al. Differential roles of
IL-1 and TNF-α on graft-versus-host disease and graft versus leukemia. J Clin Invest
1999;104(4):459-67.
[67] Matte CC, Cormier J, Anderson BE, Athanasiadis I, Liu J, Emerson SG, et al. Graft-
versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell
killing. Blood 2004;103(11):4353-61.
[68] Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J. Role of tumor necrosis
factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol
Blood Marrow Transplant 2003;9(5):292-303.
384
Search WWH ::
Custom Search